OTC Sedation Warning Effectiveness To Be Considered By FDA/NTSB
This article was originally published in The Tan Sheet
Executive Summary
The inability of consumers to recognize they have impaired motor skills after taking potentially sedating OTC antihistamines likely will be discussed at a joint FDA/National Transportation Safety Board meeting Nov. 14-15
You may also be interested in...
OTC Sedative Effects Subject Of FDA/NTSB Meeting In November
Data gathered at a November meeting on potential transportation risks associated with the use of sedating medicines by vehicle operators could bolster support for an FDA-mandated OTC switch of second-generation antihistamines.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands